Exome Sequencing: current and future perspectives

Amanda Warr*, Christelle Robert*, David Hume*, Alan Archibald*, Nader Deeb§ and Mick Watson*

* The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush, Edinburgh EH25 9RG, UK
§ Genus plc., Hendersonville, TN 37075, USA

ABSTRACT  The falling cost of DNA sequencing has made the technology affordable to many research groups, enabling researchers to link genomic variants to observed phenotypes in a range of species. This review focusses on whole exome sequencing and its applications in humans and other species. The exome has traditionally been defined to consist of only the protein coding portion of the genome; a region where mutations are likely to affect protein structure and function. There are several commercial kits available for exome sequencing in a number of species and, owing to the highly conserved nature of exons, many of these can be applied to other closely related species. The data set produced from exome sequencing is many times smaller than that of whole genome sequencing, making it more easily manageable and the analysis less complex. Exome sequencing for disease gene discovery in humans is well established and has been used successfully to identify mutations that are causative of complex and rare diseases. Exome sequencing has also been used in a number of domesticated and companion species. The successful application of exome sequencing to crops has yielded results that may be used in selective breeding to improve production in these species, and there is potential for exome sequencing to provide similar advances in livestock species that have not yet been realised.

INTRODUCTION

The completion of a reference genome sequence for humans took more than 200 scientists over a decade in a project that cost almost $3 billion to complete (International Human Genome Sequencing Consortium 2004). Over the past decade the price of genome sequencing has plummeted, much of the work has become automated and methods have improved. These advances mean complete genomes can be sequenced quickly and affordably. Human genome sequencing is a special case and enjoys much lower cost-per-gigabase than other species due to Illumina’s HiSeq X platform (Watson 2014). Sequencing can allow for the identification of genetic variants that affect heritable phenotypes including important disease-causing mutations and natural variation that can be exploited to improve crops and livestock. Despite the significant improvement in sequencing technology, sequencing whole genomes to a depth sufficient to find variants that affect phenotypic expression is expensive when compared with targeted sequencing. This review will focus on exome sequencing: a method which targets only a subset of the genome, often the protein coding portion, significantly reducing the sequencing space and subsequently the cost. Details of the method, available platforms, uses in humans and other species and its benefits over whole genome sequencing (WGS) will be discussed.

WHAT IS EXOME SEQUENCING?

The exome has been traditionally defined as the sequence encompassing all exons of protein coding genes in the genome and covers between 1% and 2% of the genome, depending on species. It may also be extended to target functional non-protein coding elements (e.g. miRNA, lincRNA etc.) as well as specific candidate loci. There are two main categories of exome capture technology: solution-based and array-based.

In solution-based whole exome sequencing (WES), DNA samples are fragmented and biotinylated oligonucleotide probes (baits) are used to selectively hybridise to target regions in the genome. Magnetic streptavidin beads are used to bind to the biotinylated probes, the non-targeted portion of the genome is washed away and the polymerase chain reaction (PCR) is used to amplify the sample, enriching the sample for DNA from the target region. The sample is then sequenced before proceeding to bioinformatic analysis. Array-based methods are similar except that the probes are bound to a high-density microarray. The array-based method was the first to be used in exome capture (Albert et al. 2007), but it has largely been supplanted by solution-based methods, which require less input DNA and are consequently potentially more efficient; however, studies by Asan et al. (2011) and Bodi et al. (2013) found that NimbleGen’s Sequence Capture Array performed better than the solution-based alternatives in low GC content regions; had high sensitivity and read mapping rates; and single nucleotide polymorphism (SNP) detection from these reads was more specific to the target region. This suggests that a niche may remain for the older tech-
EXOME CAPTURE PLATFORMS

There are several differences between the available platforms, which are constantly being updated and improved. The major providers of exome capture platforms are NimbleGen, Agilent and Illumina and each have different designs and strengths (Summarised in Table 1). The discussion of the characteristics of each platform will focus on the solution-based human kits; the performance of kits for other species has not been subjected to the same level of comparison.

NimbleGen’s SeqCap EZ Exome Library has the highest bait density of any of the platforms, utilising short (55–105 bp), overlapping baits to cover the target region (Clark et al. 2011). This approach has been found to be an efficient method for enrichment with the least amount of sequencing needed to cover the target region and sensitively detect variants (Clark et al. 2011) and also has a high level of specificity showing fewer off-target reads than other platforms (Clark et al. 2011; Sulonen et al. 2011). Importantly, this bait design has been found to show greater genotype sensitivity and more uniformity of coverage in difficult to sequence regions, such as areas of high GC content, than the other platforms (Asan et al. 2011; Sulonen et al. 2011; Bodi et al. 2013).

Agilent’s SureSelect Human All Exon Kit is the only platform to use RNA probes, with the other platforms opting for DNA probes. The baits used are longer than those used in NimbleGen’s platform (114–126 bp) and the corresponding target sequences are adjacent to one another rather than overlapping (Clark et al. 2011). This design has been found to be good at identifying insertions and deletions (indels) as longer baits can tolerate larger mismatches (Clark et al. 2011; Bodi et al. 2013). Chilamakuri et al. (2014) found that the Nextera kit had increased coverage of high GC content areas due to altered bias in the transposome technology used during fragmentation, decreasing its overall uniformity; however recent changes to the protocol in the new versions may have improved this. They also found that out of all platforms tested, the Nextera platform retained the fewest designs, however in practice the allele bias has been similar to other platforms (Asan et al. 2011; Bodi et al. 2013). The platform has been found to produce fewer duplicate reads than NimbleGen, but also fewer high quality reads (Sulonen et al. 2011). Bodi et al. (2013) found that Agilent had a higher alignment rate and fewer PCR duplicates than NimbleGen, but also had less uniform coverage.

Illumina’s TruSeq Exome Enrichment Kit uses 95 bp probes that leave small gaps in the target region, with paired end reads extending outside the bait sequence during sequencing to fill the gap. This design has been found to have a high percentage of off-target enrichment (Clark et al. 2011) which reduces its target efficiency compared to the other platforms. This kit detects more SNVs in the untranslated regions (UTRs) than the other platforms (Clark et al. 2011), though comparisons of performance with NimbleGen and Agilent’s “+UTR” kits have yet to be performed. Following filtering for duplicates, multiple mappers, improper pairs and off-target reads, Chilamakuri et al. (2014) found that this platform retained fewer reads (54.8%) than NimbleGen (66%) or Agilent (71.7%). At high read counts (>50M), this platform outperformed Agilent’s SureSelect in downstream identification of indels (Clark et al. 2011).

Illumina’s Nextera Rapid Capture Exome and Expanded Exome kits are similar to the TruSeq kit in their probe design. They differ from the other kits in that they use transposomes to fragment the genomic DNA, whereas the other platforms use ultrasonication. These kits have not been extensively compared to the other platforms with only Chilamakuri et al. (2014) having included Nextera in a comparison study. At the time of the study there was only one Nextera kit which was the Expanded Exome version: the kit with the larger target region of the two. The Expanded Exome kit shares a target region with the TruSeq kit which includes UTRs and miRNAs. Chilamakuri et al. (2014) found that the Nextera kit had increased coverage of high GC content areas due to altered bias in the transposome technology used during fragmentation, decreasing its overall uniformity; however recent changes to the protocol in the new versions may have improved this. They also found that out of all platforms tested, the Nextera platform retained the fewest reads remaining following filtering.

Table 1 Summary of the differences between the solution-based exome sequencing platforms

<table>
<thead>
<tr>
<th></th>
<th>NimbleGen’s SeqCap EZ Exome Library</th>
<th>Agilent’s Sure Select Human All Exon Kit</th>
<th>Illumina’s TruSeq Exome Enrichment Kit</th>
<th>Illumina’s Nextera Rapid Capture Exome Kit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Probe Size*</td>
<td>55–105 bp</td>
<td>114–126 bp</td>
<td>95 bp</td>
<td>95 bp</td>
</tr>
<tr>
<td>Probe Type</td>
<td>DNA</td>
<td>RNA</td>
<td>DNA</td>
<td>DNA</td>
</tr>
<tr>
<td>Coverage Strategy</td>
<td>High-density, overlapping probes</td>
<td>Adjacent probes</td>
<td>Gaps between probes</td>
<td>Gaps between probes</td>
</tr>
<tr>
<td>Fragmentation Method</td>
<td>Ultrasonication</td>
<td>Ultrasonication</td>
<td>Ultrasonication</td>
<td>Transposomes</td>
</tr>
<tr>
<td>Target region size (Human)b</td>
<td>64Mb</td>
<td>50Mb</td>
<td>62Mb</td>
<td>62Mb</td>
</tr>
<tr>
<td>Reads remaining following filteringc</td>
<td>66%</td>
<td>71.7%</td>
<td>54.8%</td>
<td>40.1%</td>
</tr>
<tr>
<td>Major strengths</td>
<td>(i) High sensitivity and specificity (ii) Most uniform coverage in difficult regions (iii) Better coverage of indels (ii) High alignment rate (iii) Fewer duplicate reads than other platforms (i) Good coverage of UTRs and miRNAs (i) Good coverage of UTRs and miRNAs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Major weaknesses</td>
<td>(i) More duplicate reads than Agilent (ii) Lower alignment rate than Agilent (i) Fewer high quality reads than NimbleGen (i) High off-target enrichment (i) High off-target enrichment (ii) Coverage bias for high GC content areas reducing uniformity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-human supported</td>
<td>✔</td>
<td>☑</td>
<td>✗</td>
<td>☑</td>
</tr>
</tbody>
</table>

* As described in Clark et al. (2011) - NimbleGen SeqCap EZ v2.0, Agilent SureSelect Human All Exon 50Mb, Illumina TruSeq Exome Enrichment
b For NimbleGen SeqCap EZ v3.0, Agilent SureSelect V5, and Illumina TruSeq and Illumina Nextera original versions
c Filtering for duplicates, multiple mappers, improper pairs and off-target reads, data from Chilamakuri et al. (2014)
reads after filtering for duplicates, multiple mappers, improper pairs and off-target reads, at 40.1%.

Chilamakuri et al. (2014) compared the target regions of the human kits from three providers (NimbleGen SeqCap EZ v3.0 ~ 64.1Mb; Agilent SureSelect V4 ~ 51.1Mb; and Illumina TruSeq and Illumina Nextera original version and protocol ~ 62.08 Mb). Despite the fact that all of the platforms are targeting the human exome, there is surprisingly little overlap between the three designs with just 26.2 Mb covered by all three target regions. NimbleGen’s and Agilent’s coverage are more similar to one another than are to Illumina’s; this is likely due to the large amount of UTRs covered in Illumina’s target region. Illumina has 22.5Mb of targets unique to their platforms and 21.8Mb of these are UTRs. NimbleGen and Agilent have 16.1Mb and 7Mb of unique targets, respectively. It would be interesting to see how NimbleGen and Agilent’s “+UTR” kits compare to Illumina in SNV calling, particularly in UTRs.

Currently, in addition to human kits, NimbleGen offer capture kits for maize, barley, wheat, soy, mouse and pig exomes and Agilent offer capture kits for mouse, cattle and zebrafish exomes. Both providers also offer the opportunity to design custom kits for other species. The kits for non-human species use similar bait designs and protocols to the providers’ human kits. Both manufacturers offer a flexible design process allowing for modifications to improve coverage for specific regions and purposes.

USES IN HUMANS
The first successful use of WES to diagnose and inform subsequent treatment in a human patient was in the identification of the causal variant of a rare form of Inflammatory Bowel Disease (IBD) in an infant (Worthy et al. 2011). In this case conventional diagnostics had failed to find an explanation for the patient’s severe symptoms and doctors needed to understand the underlying cause of the symptoms before they could decide how to treat the child. A multidisciplinary team combined clinical phenotyping, exome sequencing, bioinformatics and functional studies, eventually finding the causative mutation which influenced the future treatment of the child. The analysis of the exome data was hampered by the relative lack of software designed for this purpose at the time and researchers had to manually inspect over 2000 variants. Through filtering and manual inspection the candidate pool was reduced to 70 genes exhibiting hemi- or homozygous variants. Of these only eight variants were novel and predicted to be damaging to protein function. Analysis of evolutionary conservation identified two variants that were located in highly conserved sequences and one of these had a high null genotype frequency. This left a single hemizygous, non-synonymous variant in the X-linked inhibitor of apoptosis (XIAP) gene. The child was diagnosed with X-linked lymphoproliferative disease 2, exhibiting a novel IBD-like manifestation caused by loss of tolerance to commensal organisms in the digestive system. This diagnosis allowed for effective treatment through allogeneic hematopoietic progenitor cell transplant. The unusual manifestation of the condition meant that the patient was unlikely to have been diagnosed without the exome sequence data.

Following the success of this initial diagnosis, exome sequencing has been used extensively to diagnose novel diseases and find novel causative mutations for known disease phenotypes. Exome sequencing is useful in human medicine for diagnosis of particularly difficult to diagnose patients, diagnosis of young patients who may not yet exhibit a full spectrum of symptoms (Iglesias et al. 2014), prenatal diagnosis (Iglesias et al. 2014; Xu et al. 2014) and early diagnosis of debilitating disease (Bras and Singleton 2011; Sassi et al. 2014). In addition to reaching a diagnosis, finding the causative mutation can allow for alteration of treatment, prevention of further invasive testing, accurate prognoses, and confirmed diagnoses which are essential for eligibility for benefits and access to clinical trials (Grossmann et al. 2011; Rabbani et al. 2012; Taneri et al. 2012; Iglesias et al. 2014) and in the future may allow for more targeted treatment.

Exome sequencing in human medicine benefits from the availability of large databases of known SNPs, known pathogenic variants and control genomes; during analysis variants found in these databases can generally be excluded when looking for novel variants, significantly reducing the variant pool. The Exome Aggregation Consortium (ExAC) has created a user-friendly database containing the exome sequences of over 60,000 unrelated individuals, which is freely available (Exome Aggregation Consortium (ExAC) 2014). The exomes have been analysed using a uniform bioinformatic pipeline and are from individuals with adult-onset diseases. This provides researchers with a large set of reference exomes which should be free from homozygous variants that cause childhood-onset Mendelian diseases. The database provides a wealth of information such as depth of coverage, genotype quality, allele frequency and variant consequences. The filtering capabilities and large number of exomes will simplify the process of prioritising variants when using exome sequencing as a diagnostic tool, particularly in children.

Where many unrelated, affected individuals are available, an ‘overlap’ strategy can be used to simplify analysis and search for common variants likely to affect gene function (Johansson et al. 2012). If there is a known inheritance pattern this can be used to search for specific genotype zygosity. Sequencing of multiple affected related individuals can also increase the power of the analysis (Johnson et al. 2010; Shi et al. 2011). In rare diseases, case-parent trios can be used to exclude non-pathogenic variants found in the parents (Smith et al. 2014). However, single patient sequencing may be sufficient to identify the causative mutation (Wang et al. 2011; Worthy et al. 2011; Xu et al. 2014). Analysis examining how conserved an amino acid sequence is through evolution and between genes in a family can help to increase the confidence of a mutation having a deleterious effect (Wang et al. 2011; Johansson et al. 2012; Sassi et al. 2014; Smith et al. 2014; Xu et al. 2014).

Examples of diseases for which exome sequencing has been used to detect a causative variant include Leber Congenital Amaurosis (Wang et al. 2011), Alzheimer’s Disease (Sassi et al. 2014), Maturity-Onset Diabetes of the Young (Johansson et al. 2012), High Myopia (Shi et al. 2011), Autosomal Recesive Polycystic Kidney Disease (Xu et al. 2014), Amyotrophic Lateral Sclerosis (Johnson et al. 2010), immunodeficiency leading to infection with human herpes virus 8 causing Kaposi Sarcoma (Byun et al. 2010), Acromelic Frontonasal Dystoysis (Smith et al. 2014) and a number of cancer predisposition mutations (e.g. Yan et al. 2011; Greif et al. 2012; Snape et al. 2012; Kiiski et al. 2014; Cai et al. 2015).

The Deciphering Developmental Disorders (DDD) project aims to develop a scalable exome sequencing workflow to facilitate the translation of the method from the research environment to a clinical environment. So far over 1,000 children with undiagnosed developmental disorders and their parents have been sequenced with plans to increase this number to 12,000 patients. With diagnostic yields up to 31% in the children sequenced so far, this project demonstrates the future potential of the method in a clinical setting (Gecz and Corbett 2015; Wright et al. 2015; The Deciphering Developmental Disorders 2015).

USES IN OTHER SPECIES
Variants discovery for agricultural improvement
Not all protein-altering variants cause disease (MacArthur and Tyler-Smith 2010). To understand the potential of exome sequencing in areas other than disease variant discovery, which is the main focus in human research, we can look to studies using the technique to sequence agricultural species.
Plant genomes can be extremely complex, repetitive and are often polyploid; as a result some of the most economically important crops are not well suited for genome re-sequencing studied. For example, Bread Wheat (*Triticum aestivum*) has an allohexaploid (AABBDD) genome around 17Gb in size (Brenchley et al. 2012; The International Wheat Genome Sequencing Consortium 2014). This is likely too large for subsequent WGS studies at the current price of sequencing and data storage. Wheat is an extremely important crop for both human and livestock consumption and genetic improvement is slow; with the human population increasing and additional challenges from environmental changes it is essential to gain a better understanding of the crop in order to improve it. An exome capture kit has been designed for wheat based on the accumulated transcriptome data (Winfield et al. 2012). The capture region for this kit is 56.5Mb, which is around the lower estimated size of one diploid wheat exome, and owing to similarity between the three genomes may be sufficient to capture most of the exome data from the whole allohexaploid genome. This kit has been used to identify induced mutations in the genome to aid studies investigating gene function, a use that was also applied to the rice (*Oryza sativa*) exome in the same study (Henry et al. 2014) and the soybean (*Glycine max*) exome in a separate study (Bolon et al. 2011). WES in soybean has also been used to identify unwanted intracultivar genetic heterogeneity in the exome that may affect the plant’s phenotype (Haun et al. 2011).

The genome of barley (*Hordeum vulgare*) has not been fully sequenced. Barley’s genome is smaller than wheat’s at around 5Gb, but is still larger than is practical for routine whole genome sequence analysis and contains repetitive elements that complicate the genome's assembly. A gene space assembly has been produced (The International Barley Genome Sequencing Consortium 2012) and a barley exome capture kit has been developed based on this assembly (Mascher et al. 2013). The kit has since been used to identify a mutation involved in early maturation, a trait relevant to production (Pankin et al. 2014).

Exome capture in barley has also been used to identify a gene causative of many-noded dwarfism (mnd) using mapping-by-sequencing (Mascher et al. 2014). The mnd phenotype is a shorter plant with more, narrower leaves than the wild type. The mutant in this study was created using X-ray mutagenesis; a technique which often causes large deletions. An F2 population between mutant and wild type phenotypes was created and 18 mutant individuals and 30 wild type individuals were exome sequenced. From these sequences SNPs were identified and allele frequencies of these were used to identify an allele over represented in the mutant group. Researchers queried the sequencing reads for exome targets that were present in the wild type but not the mutant. This lead to the identification of a candidate gene (*MLOC_64838.2*, now HvMND), which has a homolog known to play a role in a similar phenotype in rice. Screening of other mutants showing this phenotype found a variety of null mutations in this gene. The family to which this gene belongs is known to have effects on important production traits and may include good selection targets to improve production.

Identification of new genetic markers

Robert et al. (2014) have designed exome capture probes for the pig, used these to sequence the exomes of 96 healthy pigs and identified potentially deleterious variants. Bioinformatic analysis identified 236,608 high confidence predicted variants and 28,115 predicted indels in the target region. This work revealed notable gaps in the current Ensembl *S.scrofa* genome annotation and identified a large number of potential protein truncating variants. As the pigs tested were healthy, it is possible that some of these protein truncating variants have phenotypic effects on traits other than those relating to the health of the pigs or to the production traits currently under selection. This work is an important step in identifying phenotype altering variants in the pig: a production animal and medical model.

The barley exome kit has been used to differentiate between markers of *H. vulgare* L. and *H. bulbosum* L.; *H. bulbosum* L. is a wild species that has superior pathogen resistance and tolerance compared to the domestic species and the two can be crossed to improve the domesticated crop, however negative linkage drag on production traits has hampered its use in elite barley lines. Using exome sequencing to identify specific markers can allow selective crossing to be used to incorporate the beneficial variants without incorporating linked variants that are detrimental to production (Wendl et al. 2014). Similarly, the wheat exome kit has allowed for discovery of previously unidentified markers in the genome which can be used in future genetic studies and marker assisted selection (Allen et al. 2013).

Black cottonwood (*Populus trichocarpa*) has had an exome capture kit designed (Zhou and Holliday 2012). *P. trichocarpa* is a model organism and was the first tree to have its whole genome sequenced (Tuskan et al. 2006). The tree is used in lumber production and in cosmetics. The tree has experienced a whole genome duplication fairly recently and the exome study found that this does not appear to have had an effect on SNP detection through exome sequencing (Zhou and Holliday 2012). There is potential to use the identified markers to improve production in this species.

**Health traits**

As with exome sequencing in humans, exome sequencing has been used in other mammals to discover variants associated with health traits. WES has been used in conjunction with a genome wide association study to identify a frameshift mutation causing blindness in Phalène dogs (Ahonen et al. 2013). In cattle (*Bos taurus*), WES has been used successfully to identify strong candidate variants for haplotypes relating to reduced fertility rates in Holsteins which can be used to selectively breed against these detrimental haplotypes (McClure et al. 2014).

**Special considerations for non-human species**

For many species, the reference genome is not completed to the same standard as the human genome; many species have only a draft genome or, as discussed for barley, no reference genome. This is an important consideration when using WES in non-human species. Poor annotation of genomes mean that in the design of capture probes, causative genes may be missed because they are not annotated whereas with whole genome sequencing, the data will be there whether the gene is annotated or not. Where available, including predicted genes identified from RNA-sequencing data may be beneficial to maximize coverage of functional elements in poorly annotated genomes. For example, Robert et al. (2014) added an additional 14Mb of data to the capture region in pigs using EST evidence. Additionally, errors in the reference genome will greatly increase the number of false-positive variant calls in these species. This increases computational burden and forces more stringent filtering which may inadvertently discard causative variants.

WES may be especially useful for model organisms, particularly where the sequences of large numbers of individuals are needed. The expense of WGS on large cohorts makes it less feasible in animal studies than human studies, particularly in species with fairly large genomes such as mice (~3.5Gb) and zebrafish (~1.5Gb), both common model organisms. Sequencing a smaller portion of the genome, particularly if candidate regions are known and can be targeted, would be more cost-effective, allow deeper coverage and potentially increase the number of individuals that can be used in these studies.

The genomes of animals have different levels of linkage disequilibrium (LD), which are often high in domestic species and model organisms with limited effective population sizes. The level of LD may also
vary by breed, as demonstrated in the domestic dog (Stern et al. 2013). When using exome sequencing to identify causal variants, high LD may lead to the identification of a benign variant that is in LD with the causative variant. In this case, the causative variant may have been missed in variant calling or lie outside the sequence space; it is therefore important to consider the known function of the element the candidate variant is associated with and the predicted effect of the variant on function. Additionally, efforts to sample individuals that are as outbred as possible may help to reduce this problem. Another consideration with high LD is that it may be possible to use this information in imputation, as has been done with other technologies such as imputing genotypes from SNP arrays (Hickey et al. 2012), from WGS data (Deelen et al. 2014; Gudbjartsson et al. 2015) and from human exome data (Auer et al. 2012). The larger haplotypes associated with high LD increase the accuracy and reduce the computational burden associated with imputation. Imputation may be less accurate than sequencing; however it allows for a larger numbers of individuals to be used at lower coverage and may help to reduce problems associated with variable coverage in exome sequencing.

EXOME CAPTURE TRANSFERABILITY BETWEEN SPECIES
The Neanderthal exome was successfully sequenced by Burbano et al. (2010) using an exome capture kit designed for the human exome. The study compared the Neanderthal exome to human exomes and found 88 fixed substitutions in 83 genes in the human exomes; these substitutions did not appear to be a result of positive selection and may be a result of accelerated genetic drift from reduced effective population size in humans following historical bottlenecks or reduced purifying selection.

The kit designed for cattle can also be applied to other bovid species; Cosart et al. (2011) demonstrated that the kit could be successfully used to capture the exomes of, and identify SNPs in, zebu (Bos indicus) and American Bison (Bison bison). This transferability of exome capture kits, as also demonstrated in studies involving the sequencing of Neanderthals and non-human primates using human capture kits (Burbano et al. 2010; Vallender 2011), is possible because despite millions of years of divergence, functional elements tend to be highly conserved.

WHY NOT USE GENOME SEQUENCING?
With the price of sequencing falling as rapidly as it has done over the past decade, questions have been raised concerning WES’s usefulness in the era of affordable WGS. However, WGS is still more expensive than WES. The costs of WES consist of the cost of the capture plus the cost of sequencing, whereas WGS consists only of the sequencing costs. If we assume that the cost of capture remains fixed, then as the costs of sequencing fall, the cost of WGS will approach the cost of WES. However, at present that is not the case; and it would be unwise to assume that the cost of sequence capture will not reduce.

Human genomes are a special case, in that the HiSeq X platform offers a cost-per-Gb far less than other platforms, yet is limited (contractually, rather than technically) to 30X WGS human genomes (Watson 2014). However, even given that advantage, the $1000 price tag for a 30X human genome is (in our estimate) two- to three- times the cost of a 40X human exome (depending on scale). It may be advantageous to sequence more samples using WES, and gain statistical power, than to sequence the whole genome. This means that exome sequencing relies on the accuracy of the genome annotation, so phenotype altering variants may be missed in poorly or incompletely annotated genomes. It is therefore important to take care when designing the capture region or purchasing a commercial kit to ensure any specific regions of interest are included. Exome sequencing also invariably fails to successfully capture the entire target region (Asan et al. 2011; Bodi et al. 2013; Chilamakuri et al. 2014; Roberts et al. 2014), causing even properly annotated regions to be missed. Another consideration is that exome sequencing involves a PCR stage which is known to reduce coverage of GC-rich regions (Kozarewa et al. 2009; Veal et al. 2012). New sequencing technology has allowed for sequencing of DNA without the need for DNA amplification, generating sequencing from single molecules. This technology can produce accurate, longer reads without the artefacts and biases associated with the amplification process, but the exome capture stage of WES (Shin et al. 2013). The longer read length in these third-generation sequencers is particularly beneficial for detecting structural variants and for resolving repetitive regions in assemblies and copy number variable regions (Roberts et al. 2013). However, for now the price of this long-read sequencing is still prohibitively expensive and is not commonly in use for analysis of genetic variation. In the future as these sequencers improve and prices come down they may make WGS
more attractive to researchers even if their analysis focusses solely on the protein-coding region and known functional elements.

The power of WGS on a large cohort for variant discovery has already been demonstrated by Gudbjartsson et al. (2015), who sequenced the whole genomes of 2,636 Icelanders to 20X and imputed the sequence variants into 101,584 further chip-genotyped and phased individuals from the same population. This allowed for discovery of 6,795 null mutations in 4,924 genes which may play a role in disease. They also found evidence of lethal mutations that are not found in the homozygous state, which likely impact on fertility in heterozygous couples. Imputation reduces the amount of sequencing and data storage required, though the study found that fewer null mutations were detected in the imputed data set suggesting that some mutations were missed in these individuals.

WGS will eventually take a leading role in genome interrogation; however, it will likely have to wait for data storage and analysis to improve before its full potential can be realised. In the meantime, WES provides many of the benefits of WGS with lower storage requirements and computational burden, at an affordable price. This is particularly useful in large scale studies, for example, a recent study sequenced the exomes of over 9,000 people (Schick et al. 2015). It is also useful for the sharing of information such as in the ExAC database where there are over 60,000 exomes stored. WES will likely also remain the method of choice in species with exceptionally large genomes, for example in some polyploid plant species.

CONCLUSIONS
Exome sequencing is a technology that allows interrogation of the most well understood portion of the genome: the protein-coding sequence and functional elements. Variants of interest don’t necessarily fall within the exome, but so far most of the known variants responsible for Mendelian disease have been found in the coding region and the target region can be extended to include other regions of interest. While the falling price of sequencing may soon make genome sequencing more attractive, the additional costs of data handling and downstream analysis cannot be ignored. The applications of variant discovery, particularly in disease gene identification, cannot afford to wait for data storage and processing technology to catch up to sequencing improvements. The amount of data produced by WES is far more manageable than WGS; particularly for small research groups and groups studying organisms with large genomes. WES has established itself as an important method in disease gene identification in humans, and increasingly in domestic species. The applications of WES in crop research is allowing genomic techniques to be used in species with complex genomes, potentially identifying variants important for production that can be incorporated into marker-assisted selection. At present, WES is a useful and powerful method for variant discovery within coding regions offering most of the benefits of WGS while allowing for easier analysis and storage of the data produced.

However WGS will eventually be the NGS technology of choice with regard to the investigation of genomic variations due to the more uniform coverage achieved with WGS-versus WES- including coverage within the exome (Belkadi et al. 2015) and the more uniform distribution of sequencing quality parameters (e.g. coverage depth, genotype quality) observed with WGS- versus WES-(Meynert et al. 2014; Belkadi et al. 2015). Additionally WGS extends the variation search space to the whole genome allowing for the additional detection of non-coding variants (The 1000 Genomes Project Consortium 2012), the functional impact of which is becoming easier to interpret with the systematic annotation of functional non-coding elements (The ENCODE Project Consortium 2012; Ward and Kellis 2012; Andersson et al. 2014; The Fantom Consortium et al. 2014).

Ideally -regardless of sequencing costs and storage limitations-, integrated approaches combining the advantages of both WES and WGS would be beneficial for variant discovery studies with the addition of WES-/WGS-exclusive variants with WES providing additional variants missed in low-coverage dataset (The 1000 Genomes Project Consortium 2012). Additionally, both technologies’ usefulness depend on the quality of the reference assembly that the sequenced reads are mapped to; poor quality references increase the number of false-positive variants identified in the analysis, which inevitably leads to more stringent filtering, increasing the potential for discarding a variant of interest. In the future, the improvement of reference assemblies, bioinformatic tools and sequencing technology will be necessary to improve the power of variant discovery techniques.

The term “exome” may no longer be appropriate for a technique which is simply a subset of the more generic technique of sequence capture. It is already possible to extend the exome capture region beyond protein coding genes to capture non-coding genes, and regulatory elements such as promoters and enhancers. In this way, we may sequence all of the functional areas of a genome without the cost of sequencing everything. Indeed, as clinically important variants are discovered, the paradigm may change to sequencing small panels of genes that are known to be relevant to disease, as is common in cancer genomics.

REFERENCES
Belkadi, A., A. Bolze, Y. Itan, A. Cobat, Q. B. Vincent et al., 2015 Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants. Proceedings of the National Academy of Sciences.


Cosart, T., A. Beja-Pereira, S. Chen, S. B. Ng, J. Shendure et al., 2011 Exome-wide DNA capture and next generation sequencing in domestic and wild species. BMC Genomics 12:347.


Mardis, E. R., 2010 The $1,000 genome, the $100,000 analysis? Genome Med 2 (11):84-84.


The International Wheat Genome Sequencing Consortium, 2014 A chromosome-based draft sequence of the hexaploid bread wheat (Triticum aestivum) genome. Science 345 (6194).


